More News

4 July 2024

Pentixapharm Acquires Target Discovery Business of Glycotope

1 July 2024

Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer

27 June 2024

2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million

26 June 2024

TRexBio Announces Collaboration Partner Lilly Has Initiated a Phase 1 Study of TRB-051 for Autoimmune and Inflammatory Diseases

25 June 2024

BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed Into Portfolio

25 June 2024

Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal

19 June 2024

Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing Therapeutics Targeting Neurological Diseases

19 June 2024

Belharra Therapeutics Announces Strategic Collaboration with Sanofi to Advance Discovery of Novel Small Molecule Therapeutics for Immunological Diseases

13 June 2024

AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease

9 June 2024

GSK accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies

1 June 2024

Anocca AB and Shinobi Therapeutics Announce Strategic Partnership to Develop Allogeneic TCR-T Cell Therapies in Oncology

30 May 2024

Full-Life Technologies Announces Clearance from FDA of IND Application for 225Ac-FL-020 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

23 May 2024

Orna Therapeutics Announces Strategic Acquisition of ReNAgade Therapeutics to Solidify Leadership in Circular RNA Therapies

21 May 2024

Aktis Oncology enters into strategic collaboration with Lilly to discover and develop novel anticancer radiopharmaceuticals

14 May 2024

NEOsphere Biotechnologies partners with Kymera Therapeutics for Novel Molecular Glue Target Discovery

14 May 2024

Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy

14 May 2024

AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders

10 May 2024

Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease

30 April 2024

TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

29 April 2024

Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion

23 April 2024

Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing

23 April 2024

Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists

22 April 2024

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

19 April 2024

Metsera Launches to Lead the Next Generation of Medicines for Obesity and Metabolic Diseases

16 April 2024

Evergreen Theragnostics Completes $26M Capital Raise to Advance Novel Radiopharmaceutical Pipeline into the Clinic, Prepare for First Commercial Product Launch, and Expand Industry-Leading CDMO Services

9 April 2024

Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6

6 April 2024

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

5 April 2024

MiNA Therapeutics Enters Research Collaboration with Nippon Shinyaku to Develop RNAa Therapeutics Targeting Rare Neurodegenerative Diseases

3 April 2024

Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences

25 March 2024

Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

B7-H4 Targeted Antibody Therapy Pipeline Review

Report Package: Claudin 18.2-Targeted Immunotherapeutics

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review

DLL3-Targeted Immunotherapy Candidates Pipeline Review

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

Report Package: “Drug the Undruggable” Technologies

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing